| Date Checked | 2026-06-19 21:32:45 |
|---|---|
| Graham Number | (PB)nan vs (PE)0.00 |
| Over / Under Value Percentage | 0.00% vs 0.00% |
| Dividend Yield | 0.00% |
| Dividend Date | None |
| Symbol | BEAM |
| AssetType | Common Stock |
| Name | Beam Therapeutics Inc |
| Description | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts. |
| CIK | 1745999 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | BIOTECHNOLOGY |
| Address | 238 MAIN STREET, CAMBRIDGE, MA, UNITED STATES, 02142 |
| OfficialSite | https://beamtx.com |
| FiscalYearEnd | December |
| LatestQuarter | 2026-03-31 |
| MarketCapitalization | 3009731000 |
| EBITDA | -349251008 |
| PERatio | 0 |
| PEGRatio | None |
| BookValue | 11.71 |
| DividendPerShare | None |
| EPS | -0.49 |
| RevenuePerShareTTM | 1.597 |
| ProfitMargin | -0.402 |
| OperatingMarginTTM | -3.378 |
| ReturnOnAssetsTTM | -0.158 |
| ReturnOnEquityTTM | -0.0577 |
| RevenueTTM | 164011000 |
| GrossProfitTTM | -240930000 |
| DilutedEPSTTM | -0.49 |
| QuarterlyEarningsGrowthYOY | 0 |
| QuarterlyRevenueGrowthYOY | 3.249 |
| AnalystTargetPrice | 51.07 |
| AnalystRatingStrongBuy | 1 |
| AnalystRatingBuy | 14 |
| AnalystRatingHold | 2 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 0 |
| TrailingPE | - |
| ForwardPE | - |
| PriceToSalesRatioTTM | 18.35 |
| PriceToBookRatio | 2.605 |
| EVToRevenue | 12.64 |
| EVToEBITDA | -7.03 |
| Beta | 2.198 |
| 52WeekHigh | 36.44 |
| 52WeekLow | 15.6 |
| 50DayMovingAverage | 29.36 |
| 200DayMovingAverage | 26.56 |
| SharesOutstanding | 102879000 |
| SharesFloat | 87973000 |
| PercentInsiders | 1.361 |
| PercentInstitutions | 107.032 |
| ExDividendDate | None |
| naga | 0 |
| etoro | 0 |
| dateChecked | 2026-06-19 21:32:45 |
| fresh | 1 |